'Young blood' for ageing: what parabiosis and plasma exchange actually show

The idea behind "young blood" therapy — that infusing plasma from young donors can reverse ageing — comes from mouse experiments in which old animals were surgically joined to a young circulation, and it has never been shown to work in people [s1][s4]. What the more recent animal work suggests is stranger and less marketable: the benefit may come from diluting the old animal's own blood rather than from anything young blood adds, and US regulators have warned consumers that the paid young-donor infusions on sale have no proven clinical benefit [s2][s4].

Where the story starts: parabiosis

The foundational experiments used parabiosis — surgically connecting the circulatory systems of two mice. In a 2005 study, exposing an old mouse to a young systemic environment restored the function of aged muscle and liver progenitor cells, apparently by reactivating signalling pathways that had gone quiet with age [s1]. That result launched two decades of interest in "circulating factors" of youth, and a search for the specific proteins responsible.

It is genuinely interesting biology. It is also a shared-circulation experiment in mice, not a transfusion, and the leap from it to a plasma infusion sold to humans is where the evidence thins out.

The twist: dilution, not addition

The most important recent finding complicates the young-blood premise directly. In a 2020 study, researchers replaced about half the plasma of old mice with saline containing 5% albumin — a "neutral" blood exchange that dilutes the animal's own plasma factors while replacing lost albumin, adding nothing young at all [s2]. A single exchange met or exceeded the rejuvenating effects seen with young blood: better muscle repair, reduced liver fat and fibrosis, and increased hippocampal neurogenesis in the old mice [s2]. The authors argue that diluting old, self-regulating signalling proteins — not importing youthful ones — drives much of the effect, and note that a comparable human procedure, therapeutic plasma exchange, is already approved and available [s2].

If that interpretation holds, the entire "young donor" framing is looking at the wrong half of the exchange.

The real human trial is not about young blood

The strongest human evidence for plasma exchange in an age-related disease comes from the AMBAR trial — and it used the patient's own plasma removed and replaced with albumin, not young donor plasma. AMBAR randomised 347 patients (of 496 screened) with mild-to-moderate Alzheimer's disease to three plasma-exchange regimens with albumin and immunoglobulin replacement or to sham treatment [s3]. Treated patients declined less than placebo on the co-primary activities-of-daily-living measure (ADCS-ADL; P = .03, 52% less decline), with a non-significant trend on the cognitive measure (ADAS-Cog; P = .06, 66% less decline) at 14 months [s3]. The benefit was concentrated in moderate-stage patients; those with mild disease showed no change [s3]. It is a real, if modest and debated, signal — and it is evidence for removing and replacing a patient's plasma, which is consistent with the dilution idea, not for buying a bag of young blood [s2][s3].

What is actually on sale, and the warning against it

None of this is what commercial "young blood" clinics offer. Establishments in several US states have sold infusions of plasma from young donors, at up to thousands of dollars per infusion, for conditions ranging from normal ageing and memory loss to dementia, Parkinson's disease and heart disease [s4]. In February 2019 the FDA advised consumers to be cautious, stating plainly that there is no proven clinical benefit of young-donor plasma for preventing or treating such conditions, and that the large volumes involved are not guided by evidence from adequate, well-controlled trials [s4]. The agency also flagged real risks: infectious disease transmission, allergic reactions including anaphylaxis, transfusion-related acute lung injury, and circulatory overload [s4].

The honest summary

Parabiosis showed that the ageing environment inside the body is malleable — a legitimate and important finding [s1]. But the human product built on top of it inverts the likely mechanism, has no trial evidence behind it, carries transfusion risks, and has drawn an explicit regulatory warning [s2][s4]. The one human plasma-exchange result worth taking seriously is a disease trial using the patient's own blood, not a longevity infusion [s3].

It fits the pattern across this section: a striking mechanism in model organisms, marketed to consumers years ahead of any human evidence, the way senolytic drugs and NAD+ IV drips have been. The malleability of the ageing "systemic environment" is one of the hallmarks of ageing — a description of how bodies age, not yet a therapy anyone should pay thousands of dollars to buy.

This article describes research findings and is not medical advice.

Sources

1. [s1] Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature, February 2005. https://doi.org/10.1038/nature03260
2. [s2] Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin. Aging, published online May 30, 2020. https://doi.org/10.18632/aging.103418
3. [s3] A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. Alzheimer's & Dementia, published online July 27, 2020. https://doi.org/10.1002/alz.12137
4. [s4] Important Information about Young Donor Plasma Infusions for Profit. U.S. Food and Drug Administration, February 19, 2019. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-information-about-young-donor-plasma-infusions-profit